Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Gene Mutation Associated With Intracranial Aneurysm Identified

XTALKS VITALS NEWS

Aneurysm

The combined evidence suggests that the THSD1 mutation prevents epithelial cells from adhering to the extracellular matrix along the inner wall of cerebral arteries.

Share this!

December 14, 2016 | by Sarah Hand, M.Sc.

Researchers at McGovern Medical School at The University of Texas Health Science Center at Houston, have identified a genetic mutation in the THSD1 gene which has been associated with intracranial aneurysms. The same mutation that was identified in patients – the details of which were published in the journal, Stroke – was further studied in two animal models of brain bleeding.

Using whole exome sequencing, the researchers studied over 500 participants, many of whom had a family history of sudden intracranial aneurysms. From this analysis, they pinpointed the THSD1 gene, which is predicted to cause cerebral arteries to form weak areas when the gene is mutated.

When artery walls in the brain are compromised, the pressure of the bloodstream could cause the vessels to rupture. Blood from the ruptured artery can fill the subarachnoid space between the brain and surrounding tissue, leading to disability or death.

The researchers further studied the gene mutation by inducing a loss-of-function of the THSD1 gene in genetically modified zebrafish and mice. Both animal models – commonly used to model human diseases – showed cerebral hemorrhage and higher rates of mortality when the THSD1 gene was nonfunctional.



“We have known for quite a while that aneurysms can run in families, so we knew there had to be a genetic variant responsible, but it took several years of painstaking genetic detective work to get to the point where we could identify this specific mutation,” said Dr. Dong Kim, director of Memorial Hermann Mischer Neuroscience Institute at the Texas Medical Center, and the senior author on the publication. “The clue that unlocked this mystery came from sequencing the genome of a specific large family in which multiple members had suffered brain aneurysms, and the evidence linking THSD1 to this disease began to build from there. It's truly a fascinating discovery because, prior to this research, hardly anyone knew what this gene did or how it worked.”

According to Kim, the combined evidence suggests that the THSD1 mutation prevents epithelial cells from adhering to the extracellular matrix along the inner wall of cerebral arteries. Because of this defect, blood flowing through the artery slowly weakens the vessel wall, leading to bulges that have the potential to burst.

“As blood continues to rush through that artery, it bulges more and more, until at some point it can rupture,” said Kim. “By identifying the role this high-risk genetic variant of THSD1 plays in leading to the formation of intracranial aneurysm, we now have a better grasp from a molecular level of why aneurysms occur. This research serves as a solid foundation on which to continue building our scientific understanding of a disease that, until now, has been somewhat of a genetic enigma.”

Around 30,000 people in the US suffer a subarachnoid hemorrhage every year, with a prevalence of about 3 percent of the general population. Of these cases, approximately 40 percent will result in death, with the remaining patients facing profound neurological impairments.


Keywords: Gene Mutation, Aneurysm, Whole Exome Sequencing


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor

March 23, 2017 - Most US patients hoping to get their PCSK9 inhibitor medications covered by their prescription drug plan are being denied, according to two new studied conducted by Amgen.

Featured In: Biotech News


Smartphone App Created Using Apple’s ResearchKit Used to Conduct Asthma Clinical Studies

March 22, 2017 - Researchers at the Icahn School of Medicine at Mount Sinai have conducted a large-scale, observational study of asthma patients using the Apple ResearchKit framework and the Asthma Health app on patients’ iPhones.

Featured In: Clinical Trials News


IBS Patients Taking Viberzi May Be at Increased Risk of Pancreatitis

March 22, 2017 - According to a recent drug safety communication issued by the US Food and Drug Administration (FDA), patients with irritable bowel syndrome (IBS) with diarrhea should not be treated using Viberzi (eluxadoline), if they do not have a gallbladder.

Featured In: Drug Safety News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.